Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Andrew Farmery of the Nuffield Division of Anaesthetics has co-authored a paper on the first UK study of the use of ketamine intravenous infusions in people with treatment-resistant depression.

'Ketamine is a promising new antidepressant which works in a different way to existing antidepressants. We wanted to see whether it would be safe if given repeatedly, and whether it would be practical in an NHS setting. We especially wanted to check that repeated infusions didn't cause cognitive problems,' explains principal investigator Dr Rupert McShane, a consultant psychiatrist at Oxford Health and a researcher in Oxford University's Department of Psychiatry.

Read more on the University website...

Similar stories

International study finds insomnia, anxiety and depression very prevalent during first phase of COVID-19 pandemic

Researchers are recommending public health interventions to reduce the long-term adverse outcomes associated with chronic insomnia and mental health problems.

Alexander Davies wins top UKRI Future Leaders Fellowship

Alex is one of eight Oxford University academics who have been awarded significant financial funding from the UKRI Future Leaders Fellowships Scheme

New study on link between autoimmunity and pain

Patients with autoantibodies which target neuronal proteins can have pain as an under-recognised clinical manifestation.

John Jacob wins clinical academic research partnership for brain cancer project

The Medical Research Council awarded Dr John Jacob upwards of £200,000 to fund a project on brain cancer modelling.